Tom H. Johnston

3.1k citations

69 papers · 2.5k indexed · h-index 32

Cellular and Molecular Neuroscience top 1%
Neurology top 0.5%
Molecular Biology
Cognitive Neuroscience top 5%
Physiology

Co-authors: Jonathan M. Brotchie Susan H. Fox Philippe Huot James B. Koprich Naomi P. Visanji M. Gabriela Reyes Matthew Piggott Jordi Gómez-Ramírez
Topics: Parkinson's Disease Mechanisms and Treatments (48 papers)Neuroscience and Neuropharmacology Research (33 papers)Neurological disorders and treatments (25 papers)
Cited by: Neurology Cellular and Molecular Neuroscience Cognitive Neuroscience
Journals: Journal of Neuroscience Blood PLoS ONE
Partner nations: Canada United States United Kingdom

In The Last Decade

Tom H. Johnston

69 papers receiving 2.5k citations

Peers

Countries citing papers authored by Tom H. Johnston

Since Specialization

Citations

This map shows the geographic impact of Tom H. Johnston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom H. Johnston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom H. Johnston more than expected).

Fields of papers citing papers by Tom H. Johnston

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom H. Johnston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom H. Johnston. The network helps show where Tom H. Johnston may publish in the future.

Co-authorship network of co-authors of Tom H. Johnston

This figure shows the co-authorship network connecting the top 25 collaborators of Tom H. Johnston. A scholar is included among the top collaborators of Tom H. Johnston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom H. Johnston. Tom H. Johnston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Excess morbidity and mortality among survivors of childhood acute lymphoblastic leukaemia: 25 years of follow-up from the United Kingdom Childhood Cancer Study (UKCCS) population-based matched cohort 2022 ·BMJ Open ·Eleanor Kane,Sally E. Kinsey,Audrey Bonaventure,Tom H. Johnston,Jill Simpson,Debra Howell,Alexandra Smith,Eve Roman	5
2	A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease 2020 ·Experimental Neurology ·Jay S. Schneider,(unknown),(unknown),Nathaniel W. Snyder,Michael P. Hill,Jonathan M. Brotchie,Tom H. Johnston,Barry D. Waterhouse,Sandhya Kortagere	23
3	The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques 2020 ·Parkinsonism & Related Disorders ·Ronan Depoortère,Tom H. Johnston,Susan H. Fox,Jonathan M. Brotchie,Adrian Newman‐Tancredi	25
4	Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson’s Disease 2019 ·Journal of Pharmacology and Experimental Therapeutics ·Patrick A. Howson,Tom H. Johnston,Paula Ravenscroft,Michael P. Hill,Jin Su,Jonathan M. Brotchie,James B. Koprich	21
5	Symptomatic Models of Parkinson’s Disease and L-DOPA-Induced Dyskinesia in Non-human Primates 2014 ·Current topics in behavioral neurosciences ·Tom H. Johnston,Susan H. Fox	23
6	Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit 2013 ·Movement Disorders ·Karen L. Eskow Jaunarajs,David G. Standaert,Tacey X. Viegas,Michael D. Bentley,Zhihao Fang,Bekir Dizman,Kunsang Yoon,Rebecca Weimer,Paula Ravenscroft,Tom H. Johnston,Michael P. Hill,Jonathan M. Brotchie,Randall W. Moreadith	52
7	Alternating Hemiplegia of Childhood-Related Neural and Behavioural Phenotypes in Na+,K+-ATPase α3 Missense Mutant Mice 2013 ·PLoS ONE ·Greer S. Kirshenbaum,Neil Dawson,Jonathan G.L. Mullins,Tom H. Johnston,Mark J. Drinkhill,Ian Edwards,Susan H. Fox,Judith A. Pratt,Jonathan M. Brotchie,John Roder,Steven J. Clapcote	38
8	l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease 2012 ·Neuropharmacology ·Philippe Huot,Tom H. Johnston,James B. Koprich,Susan H. Fox,Jonathan M. Brotchie	34
9	The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset 2012 ·PLoS ONE ·Philippe Huot,Tom H. Johnston,Michael Gandy,M. Gabriela Reyes,Susan H. Fox,Matthew Piggott,Jonathan M. Brotchie	36
10	Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) EnantiomersIn Vitroand in the MPTP-Lesioned Primate:R-MDMA Reduces Severity of Dyskinesia, WhereasS-MDMA Extends Duration of ON-Time 2011 ·Journal of Neuroscience ·Philippe Huot,Tom H. Johnston,(unknown),James B. Koprich,M. Gabriela Reyes,Susan H. Fox,Matthew Piggott,Jonathan M. Brotchie	73
11	Experimental Models of l-DOPA-Induced Dyskinesia 2011 ·International review of neurobiology ·Tom H. Johnston,Emma L. Lane	3
12	The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates 2010 ·Movement Disorders ·Tom H. Johnston,Susan H. Fox,Matthew Piggott,Juha‐Matti Savola,Jonathan M. Brotchie	33
13	Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson’s Disease 2010 ·Journal of Pharmacology and Experimental Therapeutics ·Tom H. Johnston,Philippe Huot,Susan H. Fox,James Wakefield,(unknown),Wilmin Bartolini,G. Todd Milne,James P. Pearson,Jonathan M. Brotchie	35
14	Receptor‐activity modifying protein 1 expression is increased in the striatum following repeated L‐DOPA administration in a 6‐hydroxydopamine lesioned rat model of Parkinson's disease 2008 ·Synapse ·Joohyung Lee,Jordi Gómez-Ramírez,Tom H. Johnston,Naomi P. Visanji,Jonathan M. Brotchie	9
15	Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease 2008 ·Neurobiology of Disease ·Naomi P. Visanji,Susan H. Fox,Tom H. Johnston,Gabriela Reyes,Mark J. Millan,Jonathan M. Brotchie	79
16	The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease 2008 ·Movement Disorders ·Naomi P. Visanji,Rob M.A. de Bie,Tom H. Johnston,Andrew C. McCreary,Jonathan M. Brotchie,Susan H. Fox	31
17	Histamine H3 receptor agonists reduce L‐dopa–induced chorea, but not dystonia, in the MPTP‐lesioned nonhuman primate model of Parkinson's disease 2006 ·Movement Disorders ·Jordi Gómez-Ramírez,Tom H. Johnston,Naomi P. Visanji,Susan H. Fox,Jonathan M. Brotchie	51
18	Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease 2006 ·Movement Disorders ·Naomi P. Visanji,Jordi Gómez-Ramírez,Tom H. Johnston,(unknown),Valerie Voon,Jonathan M. Brotchie,Susan H. Fox	78
19	Alterations in GABA(B)1B and GABA(B)1C receptor gene expression in the basal ganglia and thalamus of rats bearing A nigrostriatal tract lesion 2001 ·British Journal of Pharmacology ·Tom H. Johnston,Peter Jenner,Susan Duty	1
20	Changes in GABAB1A and GABAB2 receptor gene expression in the basal ganglia and thalamus of rats with a nigrostriatal tract lesion 2000 ·British Journal of Pharmacology ·Tom H. Johnston,Peter Jenner,Susan Duty	1

About Tom H. Johnston

Tom H. Johnston is a scholar working on Neurology, Cellular and Molecular Neuroscience and Toxicology, having authored 69 papers that have together received 2.5k indexed citations. Recurring topics across this work include Parkinson's Disease Mechanisms and Treatments (48 papers), Neuroscience and Neuropharmacology Research (33 papers) and Neurological disorders and treatments (25 papers). The work is most often cited by research in Neurology (1.6k citations), Cellular and Molecular Neuroscience (1.6k citations) and Cognitive Neuroscience (391 citations). Tom H. Johnston has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Jonathan M. Brotchie, Susan H. Fox, Philippe Huot, James B. Koprich, Naomi P. Visanji, M. Gabriela Reyes, Matthew Piggott, Jordi Gómez-Ramírez, Matthew J. McIldowie and Gabriela Reyes. Their work appears in journals such as Journal of Neuroscience, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact